Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap

Oropharyngeal Carcinoma

National Cancer Institute (NCI)protein_peptidePhase 2Active

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

14 Active assets in the Oropharyngeal Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide HRYZ Biotech Co.	Phase 2	BB
Fludarabine HRYZ Biotech Co.	Phase 2	BB
Cis-Diamminedichloroplatinum Ii Loren Mell, MD	Phase 2	B
Pembrolizumab Inhibrx Biosciences, Inc	Phase 2	B
Young Til National Cancer Institute (NCI)	Phase 2	B

View all 23 →

Same molecule, other indications

Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap is also rated in:

reproductive system cancerActive

CCC

Indicative · Phase 1/2

55 / 100

View asset →

triple-negative breast carcinomaDormant

CCC

Indicative · Phase 2

55 / 100

View asset →

castration-resistant prostate carcinomaActive

CCC